Ipsen Pharma SA
Ipsen Pharma SA is a France-headquartered global biopharmaceutical company that develops and commercializes prescription medicines across oncology, rare disease, and neuroscience, serving specialist physicians, hospitals, and patients in over 30 countries. FY2025 sales reached €3.67 billion.
- Company typePublic
- Founded1983
- HeadquartersBarcelona, Spain
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ipsen Pharma SA does
Ipsen Pharma SA is a France-headquartered (Boulogne-Billancourt) global biopharmaceutical company listed on Euronext Paris (ticker: IPN) that develops and commercializes prescription medicines across three focused therapeutic areas: Oncology, Rare Disease, and Neuroscience. The company's marketed portfolio includes Dysport (botulinum toxin for spasticity, cervical dystonia, and aesthetics, with 30+ years of neuroscience expertise), the Cabozantinib franchise (tyrosine kinase inhibitor for renal cell carcinoma and other tumors), Bylvay/odevixibat (ileal bile acid transport inhibitor for progressive familial intrahepatic cholestasis), IQIRVO/elafibranor (PPAR agonist for primary biliary cholangitis), and Ojemda/tovorafenib (BRAF inhibitor for pediatric low-grade glioma, EU-approved in April 2026). Pipeline assets include corabotase, a first-in-class recombinant neuroinhibitor unveiled in 2026, and IPN60340 in acute myeloid leukemia acquired via ImCheck Therapeutics.
Ipsen generates revenue through global commercialization of these prescription medicines, primarily via direct field sales to specialist physicians, hospitals, and specialty pharmacies, supplemented by regional distribution partners in markets without direct presence. FY2025 total sales reached €3.67 billion, growing 10.9% at constant exchange rates with a 35.2% core operating margin and €754 million invested in R&D. The company operates commercial infrastructure in over 30 countries and maintains a manufacturing site at Signes, France, awarded two Shingo Gold prizes for operational excellence.
The business model centers on high-unmet-need patient populations across cancer, rare liver and neurogenetic diseases, and neurological conditions, with Ipsen holding 17% market share in the $2.87 billion global neuroendocrine tumors treatment market. Capital allocation is characterized by active M&A — ImCheck (2025), Memo Therapeutics AG (announced 2026), and Kartos Therapeutics (announced 2026) — supplemented by partnerships with academic institutions and patient organizations. The company employs over 5,000 people globally, is led by CEO David Loew, and reports full gender parity on its Executive Leadership Team.
Ipsen Pharma SA firmographics
Firmographics- Name
- Ipsen Pharma SA
- Legal name
- Ipsen Pharma SAS
- Website
- https://ipsen.com
- Company type
- Public
- Founded year
- 1983
- Operating status
- Operating
- Short description
- Ipsen Pharma SA is a France-headquartered global biopharmaceutical company that develops and commercializes prescription medicines across oncology, rare disease, and neuroscience, serving specialist physicians, hospitals, and patients in over 30 countries. FY2025 sales reached €3.67 billion.
- Ownership category
- akta.pro rank
Ipsen Pharma SA industry classification
Industry- Product category
- Specialty Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Ipsen Pharma SA is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices26 records
Markets served
Ipsen Pharma SA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Ipsen generates revenue through the global commercialization of prescription medicines across three therapeutic areas: Oncology, Rare Disease, and Neuroscience. Revenue grew 10.9% at constant exchange rates in 2025, with total sales of €3.67 billion.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Ipsen Pharma SA product offering
Product offeringCore offering
Ipsen Pharma SA develops, manufactures, and commercializes specialty prescription biopharmaceuticals across three therapeutic franchises: Oncology (treatments for neuroendocrine tumors, renal cell carcinoma, pediatric low-grade glioma, and other cancers), Rare Disease (treatments for progressive familial intrahepatic cholestasis, biliary atresia, and primary biliary cholangitis), and Neuroscience (Dysport® botulinum toxin for spasticity, cervical dystonia, and medical aesthetics). Its portfolio includes marketed drugs Dysport®, Bylvay®, IQIRVO®, Ojemda®, and the Cabozantinib franchise, supported by an R&D pipeline including corabotase and IPN60340.
Product overview
Ipsen Pharma SA is a biopharmaceutical company operating across three therapeutic areas: Oncology, Rare Disease, and Neuroscience. The company's product portfolio includes marketed medicines such as Dysport® (botulinum toxin for spasticity and aesthetics), Bylvay® (odevixibat for progressive familial intrahepatic cholestasis), IQIRVO® (for primary biliary cholangitis), Ojemda® (tovorafenib for pediatric low-grade glioma), and the Cabozantinib franchise (for renal cell carcinoma). The pipeline includes corabotase, a first-in-class recombinant neuroinhibitor for aesthetic applications, and IPN60340 for acute myeloid leukemia. Ipsen focuses on areas of high unmet medical need, developing treatments for complex tumors, rare liver diseases, and neurological conditions including spasticity.
Differentiator
Problem solved
Functional benefit
Products and services
- Dysport® (abobotulinumtoxinA) Botulinum toxin type A product used to treat adult and pediatric upper limb spasticity, cervical dystonia, and medical aesthetic conditions such as glabellar lines, supported by over 30 years of neuroscience expertise.
- Bylvay® (odevixibat) Ileal bile acid transport inhibitor approved for progressive familial intrahepatic cholestasis (PFIC) and in development for biliary atresia, addressing rare pediatric cholestatic liver diseases.
- IQIRVO® (elafibranor) PPAR agonist approved for the treatment of primary biliary cholangitis, with clinical evidence of impact on alkaline phosphatase (ALP) reduction, fatigue, and pruritus.
- Ojemda® (tovorafenib) BRAF inhibitor approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration, addressing a high unmet need in pediatric oncology.
- Cabozantinib franchise Tyrosine kinase inhibitor franchise used in the treatment of renal cell carcinoma and other solid tumors, forming a core component of Ipsen's oncology commercial portfolio.
- Neuroendocrine Tumors Portfolio Marketed oncology treatments for neuroendocrine tumors (NETs), kidney cancer, liver cancer, pancreatic cancer, thyroid cancer, prostate cancer, breast cancer, and acute myeloid leukemia, holding a 17% share of the global NET treatment market valued at USD 2.87 billion in 2025.
- corabotase (RNI™) First-in-class recombinant neuroinhibitor in development for medical aesthetic applications including glabellar lines, with Phase II data demonstrating a differentiated long-acting clinical profile.
- IPN60340 Lead clinical-stage oncology program for acute myeloid leukemia (AML) acquired through the ImCheck Therapeutics acquisition, part of Ipsen's expanding hemato-oncology pipeline.
Quantifiable outcome
- Total sales of €3.67 billion in 2025, growing 10.9% at constant exchange rates
- +5 more outcomes
Companies that use Ipsen Pharma SA
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Ipsen Pharma SA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Ipsen Pharma SA partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Memo Therapeutics AGcoreIpsen to acquire Memo Therapeutics AG, adding a first-in-class BK polyomavirus antibody to expand its rare disease portfolio. This acquisition strengthens Ipsen's rare disease pipeline with an innovative antibody candidate.
- Kartos TherapeuticscoreIpsen to acquire Kartos Therapeutics, expanding its hemato-oncology late-stage pipeline. This acquisition adds to Ipsen's growing oncology franchise and complements its existing hematology programs.
- ImCheck TherapeuticscoreIpsen's acquisition of ImCheck Therapeutics expanded its Oncology pipeline with the addition of the lead clinical-stage program IPN60340 in acute myeloid leukemia (AML).
- IRICoR / Institut de recherche en immunologie et en cancérologie, Université de MontréalcoreLong-standing partnership between Ipsen and IRICoR at Université de Montréal serves as a model of cooperation between academia and industry to accelerate targeted science. The collaboration has been ongoing for multiple years.
- World Stroke OrganizationminorIpsen collaborated with the World Stroke Organization to create the 'Neuro Connections' podcast series, bringing together specialists, patient association representatives, and healthcare professionals from around the world to address current challenges in post-stroke care.
- PFIC NetworkminorPatient organization partnership for Progressive Familial Intrahepatic Cholestasis (PFIC) awareness. Ipsen developed 'PFIC Colors' initiative to help families understand PFIC conditions and find information and support.
- Alagille Syndrome AllianceminorPatient organization partnership supporting awareness and support for patients with Alagille syndrome. Ipsen participates in Alagille Syndrome Awareness Day alongside the alliance.
- PBC FoundationminorPatient organization partnership for Primary Biliary Cholangitis (PBC) awareness. Ipsen developed the 'This is My PBC' awareness initiative and collaborates with the PBC Foundation to provide support and resources.
- Fondation IpsencoreEstablished in 1983 under the aegis of the Fondation de France, Fondation Ipsen leads social and educational projects that raise awareness of rare disease. Its mission is to ensure that all people living with rare disease are treated with respect and receive an accurate and timely diagnosis. Part of Ipsen's founding Beaufour family's nearly 100-year legacy.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Ipsen Pharma SA competitors and assessment
Company assessmentDirect peers
- Galderma: Swiss-headquartered specialty pharmaceutical company with a leading aesthetics and dermatology portfolio. Directly comparable in the medical aesthetics segment where Dysport competes, and similar in scale and growth profile.
- Almirall: Spanish-headquartered specialty pharmaceutical company with European focus on dermatology and specialty care. Comparable in size and specialty pharma model; relevant for assessing Ipsen's European commercial execution.
- Leo Pharma: Danish specialty pharmaceutical company focused on dermatology and rare disease. Comparable mid-cap European specialty pharma with similar therapeutic-area breadth and specialty-pharmacy distribution model.
- UCB: Belgian specialty biopharma with a strong neurology and rare disease pipeline. Comparable to Ipsen in scale, European base, and emphasis on specialty therapeutics with global commercial reach.
- Lundbeck: Danish specialty pharmaceutical company focused on neuroscience, including spasticity and rare neurological conditions. Directly overlaps with Ipsen's neuroscience franchise (Dysport, post-stroke spasticity) in size, therapeutic focus, and European specialty pharma positioning.
- Recordati: Italian mid-cap specialty pharmaceutical company with a similar therapeutic focus (including rare diseases and specialty oncology) and comparable European commercial footprint. Closely matches Ipsen on size, geographic mix, and specialty pharma business model.
Broad incumbents
- AbbVie: Global biopharmaceutical major whose Botox franchise is the principal Dysport competitor across both spasticity and aesthetics. A relevant broad incumbent for benchmarking commercial scale and competitive dynamics in Ipsen's core neuroscience business.
- Sanofi: French-headquartered global biopharmaceutical major with a significant rare disease and specialty care portfolio. Comparable broad incumbent for Ipsen in terms of European HQ, payer access, and rare-disease strategy.
- Novartis: Global biopharmaceutical leader holding 21% of the neuroendocrine tumors treatment market versus Ipsen's 17%. Comparable broad incumbent for assessing Ipsen's oncology franchise positioning and pipeline scale.
- Takeda Pharmaceutical: Global biopharmaceutical company with a leading rare disease franchise (built largely through the Shire acquisition). Broad incumbent for benchmarking Ipsen's rare-disease strategy, geographic reach, and pipeline depth.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Ipsen Pharma SA social profiles
Digital presenceIpsen Pharma SA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ipsen Pharma SA leadership team
Management profileNumber of profiles
Profiles16 records
Ipsen Pharma SA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ipsen Pharma SA M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ipsen Pharma SA
What does Ipsen Pharma SA do?
Ipsen Pharma SA develops, manufactures, and commercializes specialty prescription biopharmaceuticals across three therapeutic franchises: Oncology (treatments for neuroendocrine tumors, renal cell carcinoma, pediatric low-grade glioma, and other cancers), Rare Disease (treatments for progressive familial intrahepatic cholestasis, biliary atresia, and primary biliary cholangitis), and Neuroscience (Dysport® botulinum toxin for spasticity, cervical dystonia, and medical aesthetics). Its portfolio includes marketed drugs Dysport®, Bylvay®, IQIRVO®, Ojemda®, and the Cabozantinib franchise, supported by an R&D pipeline including corabotase and IPN60340.
Is Ipsen Pharma SA a public or private company?
Ipsen Pharma SA is a public company. It is classified as public and is currently operating.
When was Ipsen Pharma SA founded?
Ipsen Pharma SA was founded in 1983.
Where is Ipsen Pharma SA based?
Ipsen Pharma SA is headquartered in Barcelona, Spain, in the Europe region.
How does Ipsen Pharma SA make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Ipsen Pharma SA's main competitors?
Direct peers on record are Galderma, Almirall, Leo Pharma, UCB, Lundbeck and Recordati. Broad incumbents are AbbVie, Sanofi, Novartis and Takeda Pharmaceutical.
Does Ipsen Pharma SA have an API?
No public API is recorded for Ipsen Pharma SA.
What industry is Ipsen Pharma SA in?
Ipsen Pharma SA's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.